Peptides for Weight Loss: The Evidence-Based Guide

The weight loss drug market changed permanently in 2021. That’s when semaglutide — a GLP-1 receptor agonist peptide — showed nearly 15% body weight reduction in a landmark trial [1]. Since then, tirzepatide has pushed that number past 20% [2].

These aren’t fringe supplements or research chemicals. They’re FDA-approved peptide therapy medications backed by some of the largest obesity trials ever conducted. But the hype has outpaced the nuance, and there’s a lot you should understand before starting treatment.

Key Takeaways

• Semaglutide (Wegovy) produced 14.9% average body weight loss over 68 weeks in the STEP 1 trial — roughly 33.7 pounds [1]
• Tirzepatide (Zepbound) achieved up to 22.5% weight loss at the highest dose in SURMOUNT-1, making it the most effective weight loss peptide available [2]
• GI side effects are common but manageable — about 74% of semaglutide users reported some GI symptoms, though only ~4.2% discontinued because of them [3]
• These are long-term medications — most people regain weight after stopping, which makes understanding the commitment upfront worthwhile

Table of Contents

1. How GLP-1 Peptides Cause Weight Loss
2. Semaglutide: The STEP Trial Data
3. Tirzepatide: SURMOUNT Trial Results
4. Liraglutide: The First-Generation Option
5. Comparing the Three: Head-to-Head Numbers
6. Realistic Expectations and Timelines
7. Side Effects and Safety
8. Cost and Access
9. Who Should (and Shouldn’t) Consider GLP-1 Peptides
10. FAQ
11. Sources

How GLP-1 Peptides Cause Weight Loss

GLP-1 stands for glucagon-like peptide-1. It’s a hormone your gut naturally produces after eating. It tells your brain you’re full, slows stomach emptying, and helps regulate blood sugar.

The problem is that natural GLP-1 breaks down in minutes. Medications like semaglutide and tirzepatide are synthetic versions engineered to last much longer — days instead of minutes. This sustained activation of the GLP-1 receptor creates a persistent feeling of satiety that dramatically reduces appetite.

The Brain Connection

These peptides don’t just work in the gut. They cross into the brain and act on appetite centers in the hypothalamus, reducing hunger signals and food reward pathways [4]. That’s why patients consistently report not just eating less, but actually wanting less food. Some describe it as the “food noise” turning off.

Tirzepatide’s Dual Mechanism

Tirzepatide is different from semaglutide in one important way: it activates two receptors, not one. For a detailed breakdown of how these two drugs compare, see our semaglutide vs tirzepatide comparison. It hits both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors [2]. This dual mechanism appears to produce greater weight loss, though researchers are still working out exactly why the GIP component adds benefit.

Semaglutide: The STEP Trial Data

Semaglutide for weight loss is sold as Wegovy (subcutaneous injection) and was studied in the STEP trial program — one of the largest obesity clinical trial programs ever conducted.

STEP 1: The Headline Trial

Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition [1].

The results at 68 weeks:

• Semaglutide group: 14.9% mean body weight loss (about 33.7 lbs)
• Placebo group: 2.4% mean body weight loss
• Treatment difference: 12.4 percentage points

That’s not an average of the best responders — it’s the mean across all participants. Some patients lost considerably more. In fact, 86.4% of semaglutide users lost at least 5% of their body weight, and 50.5% lost at least 15% [1].

STEP 4: What Happens When You Stop

STEP 4 answered the question everyone asks: what happens if I stop taking it? Participants who switched from semaglutide to placebo after 20 weeks regained about two-thirds of the weight they’d lost over the following 48 weeks [5].

This isn’t a criticism of the drug — it’s the nature of obesity as a chronic condition. Blood pressure medications don’t “cure” hypertension either. But it means you should plan for long-term use if you start.

Dosing Protocol

Semaglutide is titrated slowly to minimize GI side effects:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance dose)

The escalation takes about four months. Rushing it significantly increases nausea and vomiting risk.

Tirzepatide: SURMOUNT Trial Results

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight loss) has produced the most impressive weight loss numbers of any medication to date.

SURMOUNT-1: Record-Breaking Results

The SURMOUNT-1 trial, published in the NEJM in 2022, enrolled 2,539 adults with obesity or overweight [2]. At 72 weeks, the results by dose:

• 5 mg dose: 16.0% mean weight loss
• 10 mg dose: 21.4% mean weight loss
• 15 mg dose: 22.5% mean weight loss
• Placebo: 2.4% weight loss

At the 15 mg dose, 36.2% of participants lost 25% or more of their body weight [2]. To put that in perspective, that’s the kind of weight loss previously only achievable through bariatric surgery.

SURMOUNT-1 Three-Year Data

Long-term follow-up showed encouraging durability. Most participants on continued treatment regained less than 5% from their lowest weight over three years [6]. Less than 10% regained 10% or more. This suggests that unlike many weight loss interventions, the effect doesn’t fade dramatically with time — as long as treatment continues.

Dosing Protocol

Tirzepatide also uses a slow titration:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly (optional step)
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly (optional step)
• Week 21+: 15 mg weekly (maximum dose)

Not everyone needs the 15 mg dose. Many patients get excellent results at 10 mg with fewer side effects.

Liraglutide: The First-Generation Option

Liraglutide (Saxenda) was the first GLP-1 peptide approved specifically for weight management, hitting the market in 2014. It’s a daily injection, not weekly.

SCALE Trial Results

The SCALE Obesity and Prediabetes trial enrolled 3,731 adults — one of the largest obesity studies at its time [7]. At 56 weeks:

• Liraglutide group: approximately 8% mean body weight loss
• Placebo group: approximately 2.6% weight loss
• Treatment difference: roughly 5.4 percentage points

About 63.2% of liraglutide users lost at least 5% of their body weight [7]. Those numbers are clinically meaningful — 5% body weight loss is the threshold where metabolic benefits start appearing — but they look modest next to semaglutide and tirzepatide.

Where Liraglutide Fits Today

Liraglutide is less effective than the newer options, and the daily injection schedule is less convenient than weekly dosing. However, it may still make sense for patients who don’t tolerate semaglutide or tirzepatide, or in cases where insurance covers Saxenda but not Wegovy or Zepbound.

Comparing the Three: Head-to-Head Numbers

Here’s how the three FDA-approved GLP-1 peptides for weight loss stack up based on their pivotal trials:

Semaglutide 2.4 mg (Wegovy):

• Mean weight loss: 14.9% at 68 weeks
• ≥5% weight loss: 86.4% of patients
• Dosing: Weekly subcutaneous injection
• Placebo-adjusted difference: ~12.4% [1]

Tirzepatide 15 mg (Zepbound):

• Mean weight loss: 22.5% at 72 weeks
• ≥5% weight loss: 96% of patients (estimated)
• Dosing: Weekly subcutaneous injection
• Placebo-adjusted difference: ~20.1% [2]

Liraglutide 3.0 mg (Saxenda):

• Mean weight loss: ~8% at 56 weeks
• ≥5% weight loss: 63.2% of patients
• Dosing: Daily subcutaneous injection
• Placebo-adjusted difference: ~5.4% [7]

One caveat: these trials used different populations, timepoints, and study designs. Direct comparisons require head-to-head trials, and limited data exists on tirzepatide vs. semaglutide directly. Still, the numbers suggest a clear hierarchy: tirzepatide > semaglutide > liraglutide for pure weight loss. For a deeper look at body composition data and how these peptides specifically target fat mass, see our guide on peptides for fat loss.

Realistic Expectations and Timelines

Clinical trials show averages, but individual results vary. Here’s what a realistic timeline typically looks like:

Month 1-2 (Titration Phase): Most patients lose 2-5 lbs during dose escalation. Some lose more, some plateau. The low starting dose is about tolerability, not efficacy.

Month 3-4 (Acceleration Phase): Weight loss picks up as you reach therapeutic doses. Many patients report significant appetite reduction here.

Month 5-12 (Peak Loss Phase): This is where the bulk of weight loss occurs. Most people hit their maximum rate of loss between months 4-8.

Month 12+: Weight loss gradually slows and stabilizes. Most patients reach their lowest weight between 12-18 months.

What Predicts Better Results?

Higher starting BMI generally correlates with more absolute weight lost. Women and men respond similarly in percentage terms. Combining medication with even moderate exercise and dietary changes improves outcomes beyond medication alone. Some patients also explore peptides for fat loss like tesamorelin and growth hormone secretagogues as complementary tools. The SURMOUNT-3 trial showed that tirzepatide after intensive lifestyle intervention produced 26.6% weight loss — better than either approach alone [8].

Side Effects and Safety

GI side effects are the most common issue, and they’re the main reason people stop treatment.

Gastrointestinal Effects

In the STEP 1 trial, 74.2% of semaglutide users reported at least one GI adverse event, compared to 47.9% on placebo [1]. The most common:

• Nausea: 44% (semaglutide) vs. 18% (placebo)
• Diarrhea: 30% vs. 16%
• Vomiting: 24% vs. 6%
• Constipation: 24% vs. 11%

The good news: these side effects were mostly mild to moderate, occurred mainly during dose escalation, and were transient. Only about 4.2% of participants discontinued due to GI side effects [3]. Most people who push through the first few weeks at each dose find the symptoms settle.

Serious but Rare Risks

• Pancreatitis: Reported rarely in clinical trials. Patients with a history of pancreatitis should discuss this risk with their provider.
• Gallbladder disease: Higher rates of gallstones and cholecystitis were observed, likely related to rapid weight loss itself.
• Thyroid C-cell tumors: Seen in rodent studies. The FDA requires a boxed warning, though no causal link has been established in humans. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
• Muscle loss: Rapid weight loss from any cause can include lean mass. Resistance training and adequate protein intake (1.0-1.2 g/kg/day) are strongly recommended alongside treatment.

A Note on Long-Term Safety

Semaglutide has been used for diabetes (as Ozempic) since 2017, providing several years of real-world safety data. The SELECT trial, which followed over 17,000 patients for a median of 39.8 months, showed that semaglutide actually reduced cardiovascular events by 20% compared to placebo [9]. That’s reassuring for long-term use.

Tirzepatide has a shorter track record, having been approved for diabetes in 2022. No major safety signals have emerged, but the data set is younger.

Cost and Access

Let’s talk money, because it’s often the biggest barrier.

Brand-Name Pricing (2025-2026)

• Wegovy (semaglutide): List price ~$1,349/month. Novo Nordisk’s NovoCare pharmacy offers a cash price of $499/month as of March 2025 [10].
• Zepbound (tirzepatide): Eli Lilly offers direct cash-pay vials starting at lower price points, though specific pricing varies by dose [11].
• Saxenda (liraglutide): Generally $1,000-1,300/month at list price.

Insurance Coverage

Coverage is inconsistent. Medicare began covering Wegovy for cardiovascular risk reduction (not weight loss alone) in 2025. Many commercial plans cover these medications, but prior authorization requirements are common and some employers have dropped obesity drug coverage due to cost concerns [10].

Compounded Alternatives

During the FDA shortage declaration for semaglutide and tirzepatide, compounding pharmacies were permitted to produce copies. Prices ranged from $150-500/month. However, the FDA has moved to end some of these shortage declarations, and the legal landscape for compounded versions is evolving rapidly. Quality and purity vary between compounding pharmacies.

Who Should (and Shouldn’t) Consider GLP-1 Peptides

Good Candidates

• BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia)
• People who have tried lifestyle modifications without achieving target weight loss
• Patients motivated to combine medication with exercise and dietary changes

Not Appropriate For

• Pregnant or breastfeeding women (stop at least 2 months before planned conception for semaglutide)
• Personal or family history of medullary thyroid carcinoma or MEN 2
• History of pancreatitis (relative contraindication — discuss with provider)
• People looking for a short-term “quick fix” — these work best as long-term therapy
• Anyone with an active eating disorder (these medications alter appetite signaling and should be managed carefully in this population)

FAQ

How fast do you lose weight on semaglutide?▼

Most patients notice meaningful weight loss starting around month 2-3, once they reach higher doses. The average rate in clinical trials was roughly 1-2 lbs per week during the peak loss phase (months 4-10). Total expected loss is around 15% of body weight by 15-17 months [1].

Are peptides for weight loss safe long-term?▼

The longest safety data comes from the SELECT trial, which followed semaglutide users for over 3 years and actually found cardiovascular benefits [9]. GI side effects remain the most common issue but typically improve with time. No long-term safety signals have emerged that outweigh the benefits for appropriate patients.

What happens when you stop taking GLP-1 peptides?▼

Most people regain a significant portion of lost weight. The STEP 4 trial showed roughly two-thirds of lost weight returned within a year of stopping [5]. This doesn’t mean the treatment “failed” — it means obesity is a chronic condition that usually requires ongoing management, similar to blood pressure or cholesterol medications.

Is tirzepatide better than semaglutide for weight loss?▼

Based on available trial data, tirzepatide produces more weight loss at equivalent timepoints — 22.5% vs. 14.9% at the highest doses [1][2]. We break down the full comparison in our semaglutide vs tirzepatide guide. However, individual responses vary. Some patients respond very well to semaglutide, and tolerability differences matter. Your provider can help determine the best starting point.

Can I use peptides for weight loss without a prescription?▼

No — and you shouldn’t. Semaglutide, tirzepatide, and liraglutide are prescription medications that require medical supervision. Dosing, contraindication screening, and side effect monitoring all matter. “Research peptides” sold online without prescriptions are unregulated, untested, and potentially dangerous.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID: 33567185.

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024.

3. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(3):541-551. doi:10.1111/dom.14551.

4. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932.

5. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224.

6. Aronne LJ, Sattar N, Horn DB, et al. Three-year tirzepatide treatment in the SURMOUNT-1 trial. Presented at ObesityWeek 2025.

7. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892. PMID: 26132939.

8. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918. doi:10.1038/s41591-023-02597-w.

9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.

10. Novo Nordisk NovoCare pharmacy pricing; WeightWatchers cost analysis, March 2025.

11. Eli Lilly Zepbound pricing information, 2025. pricinginfo.lilly.com/zepbound.